4//SEC Filing
Knowles Julius 4
Accession 0001209191-22-001990
CIK 0001664710other
Filed
Jan 4, 7:00 PM ET
Accepted
Jan 5, 7:14 PM ET
Size
49.2 KB
Accession
0001209191-22-001990
Insider Transaction Report
Form 4
Knowles Julius
Director
Transactions
- Sale
Common Stock
2022-01-03$56.82/sh−3,678$208,984→ 366,738 total(indirect: See footnote) - Sale
Common Stock
2022-01-03$57.83/sh−3,318$191,880→ 245,812 total(indirect: See footnote) - Sale
Common Stock
2022-01-03$58.96/sh−3,412$201,172→ 242,400 total(indirect: See footnote) - Sale
Common Stock
2022-01-04$57.99/sh−4,151$240,716→ 347,383 total(indirect: See footnote) - Sale
Common Stock
2022-01-04$58.86/sh−2,195$129,198→ 234,319 total(indirect: See footnote) - Sale
Common Stock
2022-01-03$56.82/sh−2,406$136,709→ 249,130 total(indirect: See footnote) - Sale
Common Stock
2022-01-03$57.83/sh−5,094$294,586→ 361,644 total(indirect: See footnote) - Sale
Common Stock
2022-01-03$58.96/sh−5,236$308,715→ 356,408 total(indirect: See footnote) - Sale
Common Stock
2022-01-03$59.40/sh−162$9,623→ 242,238 total(indirect: See footnote) - Sale
Common Stock
2022-01-04$54.95/sh−524$28,794→ 241,714 total(indirect: See footnote) - Sale
Common Stock
2022-01-04$56.10/sh−1,383$77,586→ 240,331 total(indirect: See footnote) - Sale
Common Stock
2022-01-04$56.95/sh−1,113$63,385→ 239,218 total(indirect: See footnote) - Sale
Common Stock
2022-01-05$57.23/sh−271$15,509→ 234,048 total(indirect: See footnote) - Sale
Common Stock
2022-01-04$56.10/sh−2,124$119,156→ 353,241 total(indirect: See footnote) - Sale
Common Stock
2022-01-05$58.20/sh−886$51,565→ 233,162 total(indirect: See footnote) - Sale
Common Stock
2022-01-05$59.00/sh−435$25,665→ 232,727 total(indirect: See footnote) - Sale
Common Stock
2022-01-03$59.40/sh−249$14,791→ 356,159 total(indirect: See footnote) - Sale
Common Stock
2022-01-04$54.95/sh−794$43,630→ 355,365 total(indirect: See footnote) - Sale
Common Stock
2022-01-04$56.95/sh−1,707$97,214→ 351,534 total(indirect: See footnote) - Sale
Common Stock
2022-01-04$57.99/sh−2,704$156,805→ 236,514 total(indirect: See footnote) - Sale
Common Stock
2022-01-04$58.86/sh−3,367$198,182→ 344,016 total(indirect: See footnote) - Sale
Common Stock
2022-01-05$57.23/sh−419$23,979→ 343,597 total(indirect: See footnote) - Sale
Common Stock
2022-01-05$58.20/sh−1,356$78,919→ 342,241 total(indirect: See footnote) - Sale
Common Stock
2022-01-05$59.00/sh−667$39,353→ 341,574 total(indirect: See footnote)
Footnotes (15)
- [F1]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.
- [F10]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $56.56 to $57.53 inclusive.
- [F11]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $57.56 to $58.55 inclusive.
- [F12]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $58.57 to $59.36 inclusive.
- [F13]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $56.63 to $57.56 inclusive.
- [F14]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $57.63 to $58.62 inclusive.
- [F15]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $58.76 to $59.25 inclusive.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $56.30 to $57.29 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (5), (6), (7), (8), (9), (10), (11), (12), (13), (14) and (15).
- [F3]The securities are held by Partners Innovation Fund, LLC ("PIF I"). Partners Innovation Fund, LLC ("Partners GP I") is the ultimate general partner of PIF I. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP I and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF I.
- [F4]The securities are held by Partners Innovation Fund II, L.P. ("PIF II"). Partners Innovation Fund II, LLC ("Partners GP II") is the ultimate general partner of PIF II. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP II and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF II.
- [F5]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $57.30 to $58.24 inclusive.
- [F6]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $58.35 to $59.33 inclusive.
- [F7]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $59.36 to $59.45 inclusive.
- [F8]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $54.50 to $55.48 inclusive.
- [F9]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $55.555 to $56.53 inclusive.
Documents
Issuer
Keros Therapeutics, Inc.
CIK 0001664710
Entity typeother
Related Parties
1- filerCIK 0001808365
Filing Metadata
- Form type
- 4
- Filed
- Jan 4, 7:00 PM ET
- Accepted
- Jan 5, 7:14 PM ET
- Size
- 49.2 KB